2025, Vol. 8, Issue 1, Part A

Author(s)
Nazifa Tabassum, Md. Mohasin Al-Nury, Swarna Tribedi, Zulfiqur Hossain Khan, MA Hamid, Kaniz Shahali Reza Snigdha and Md. Golam Mostofa and Afroza Jesmin

Abstract
Acne vulgaris is a prevalent chronic inflammatory condition of the pilosebaceous unit, commonly affecting adolescents and increasingly adults, particularly women. This study aimed to evaluate the safety and efficacy of topical Dapsone 5% gel in treating inflammatory acne vulgaris. A clinical trial was conducted in the Department of Dermatology & Venereology, Mugda Medical College and Hospital, Dhaka, from April 2023 to April 2024, involving 60 patients diagnosed with acne vulgaris. Participants applied topical Dapsone 5% gel twice daily for 12 weeks and were followed up at 4, 8, and 12 weeks. Data were analyzed using SPSS and Microsoft Excel, with a significance level set at p<0.05. The mean age of participants was 23.2±5.7 years, with a majority being female (78.3%). Progressive reductions in acne lesion scores were observed across follow-ups, with the mean total acne score reducing from 14.07±1.81 at the 4th week to 3.87±0.69 at the 12th week. The percent reduction in acne severity from baseline to the final follow-up was 90.3±3.38%, which was statistically significant (p<0.05). Investigators’ Global Assessment (IGA) scores showed most patients achieved near-clear to clear skin by the end of the study. No severe adverse effects were reported. The results indicate that Dapsone 5% gel is a safe and effective treatment option for inflammatory acne, offering anti-inflammatory and antimicrobial benefits that target key pathogenic mechanisms of acne.

DOI: https://doi.org/10.33545/26649411.2025.v8.i1a.224

Pages: 26-30 | Views: 50 | Downloads: 21